FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2092532148> ?p ?o ?g. }

• W2092532148 endingPage "604" @default.
• W2092532148 startingPage "597" @default.
• W2092532148 abstract "Phase II clinical trials aim to identify promising experimental regimens for further testing in phase III trials. In this review article, we focus on phase II designs for initial predictive biomarker validation to determine if a drug should be developed for an unselected patient population or for a biomarker-defined patient subset only. Several prospective designs for biomarker-directed therapy have been proposed, differing primarily in the study population, or randomization scheme, or both. The design choice is driven by scientific rationale, marker prevalence, strength of preliminary evidence, assay performance, and turn-around times for marker assessment. The enrichment design is most appropriate when compelling preliminary evidence suggests treatment benefit in only certain marker-defined subgroups, the all-comers design is useful when preliminary evidence regarding treatment effects in marker subgroups is unclear, and adaptive designs have the most potential in the setting of multiple treatment options and multiple marker-defined subgroups. We recently proposed a 2-stage phase II design that has the option for direct assignment (i.e., stop randomization and assign all patients to the experimental arm in stage 2) based on interim analysis (IA) results. This design not only recognizes the need for randomization but also acknowledges the possibility of promising but inconclusive results after pre-planned IA. Simulation studies demonstrated that the direct assignment-option design has minimal power loss, marginal increase in type I error rates, and reasonable robustness to population shift effects. Systematic evaluation and implementation of these design strategies in the phase II setting are essential for accelerating the clinical validation of biomarker guided-therapy." @default.
• W2092532148 created "2016-06-24" @default.
• W2092532148 creator A5002528975 @default.
• W2092532148 creator A5059115952 @default.
• W2092532148 creator A5060306466 @default.
• W2092532148 date "2013-11-01" @default.
• W2092532148 modified "2023-10-14" @default.
• W2092532148 title "A review of phase II trial designs for initial marker validation" @default.
• W2092532148 cites W1969525589 @default.
• W2092532148 cites W1985046983 @default.
• W2092532148 cites W2001203833 @default.
• W2092532148 cites W2005451950 @default.
• W2092532148 cites W2005494948 @default.
• W2092532148 cites W2046081213 @default.
• W2092532148 cites W2047041970 @default.
• W2092532148 cites W2048265454 @default.
• W2092532148 cites W2071150013 @default.
• W2092532148 cites W2075826761 @default.
• W2092532148 cites W2076909095 @default.
• W2092532148 cites W2104329803 @default.
• W2092532148 cites W2105477397 @default.
• W2092532148 cites W2108710215 @default.
• W2092532148 cites W2123543995 @default.
• W2092532148 cites W2147026486 @default.
• W2092532148 cites W2155291829 @default.
• W2092532148 cites W2161630562 @default.
• W2092532148 cites W2316588149 @default.
• W2092532148 cites W2318160264 @default.
• W2092532148 cites W2325921774 @default.
• W2092532148 cites W2591144847 @default.
• W2092532148 cites W4245780845 @default.
• W2092532148 cites W4379502860 @default.
• W2092532148 cites W91108901 @default.
• W2092532148 doi "https://doi.org/10.1016/j.cct.2013.05.001" @default.
• W2092532148 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3779487" @default.
• W2092532148 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23665336" @default.
• W2092532148 hasPublicationYear "2013" @default.
• W2092532148 type Work @default.
• W2092532148 sameAs 2092532148 @default.
• W2092532148 citedByCount "20" @default.
• W2092532148 countsByYear W20925321482014 @default.
• W2092532148 countsByYear W20925321482015 @default.
• W2092532148 countsByYear W20925321482016 @default.
• W2092532148 countsByYear W20925321482017 @default.
• W2092532148 countsByYear W20925321482018 @default.
• W2092532148 countsByYear W20925321482019 @default.
• W2092532148 countsByYear W20925321482020 @default.
• W2092532148 countsByYear W20925321482021 @default.
• W2092532148 crossrefType "journal-article" @default.
• W2092532148 hasAuthorship W2092532148A5002528975 @default.
• W2092532148 hasAuthorship W2092532148A5059115952 @default.
• W2092532148 hasAuthorship W2092532148A5060306466 @default.
• W2092532148 hasBestOaLocation W20925321482 @default.
• W2092532148 hasConcept C105795698 @default.
• W2092532148 hasConcept C126322002 @default.
• W2092532148 hasConcept C141341695 @default.
• W2092532148 hasConcept C148482608 @default.
• W2092532148 hasConcept C166957645 @default.
• W2092532148 hasConcept C177713679 @default.
• W2092532148 hasConcept C185592680 @default.
• W2092532148 hasConcept C204243189 @default.
• W2092532148 hasConcept C2776957806 @default.
• W2092532148 hasConcept C2779318504 @default.
• W2092532148 hasConcept C2781197716 @default.
• W2092532148 hasConcept C2908647359 @default.
• W2092532148 hasConcept C33923547 @default.
• W2092532148 hasConcept C535046627 @default.
• W2092532148 hasConcept C55493867 @default.
• W2092532148 hasConcept C61943457 @default.
• W2092532148 hasConcept C71924100 @default.
• W2092532148 hasConcept C95457728 @default.
• W2092532148 hasConcept C99454951 @default.
• W2092532148 hasConceptScore W2092532148C105795698 @default.
• W2092532148 hasConceptScore W2092532148C126322002 @default.
• W2092532148 hasConceptScore W2092532148C141341695 @default.
• W2092532148 hasConceptScore W2092532148C148482608 @default.
• W2092532148 hasConceptScore W2092532148C166957645 @default.
• W2092532148 hasConceptScore W2092532148C177713679 @default.
• W2092532148 hasConceptScore W2092532148C185592680 @default.
• W2092532148 hasConceptScore W2092532148C204243189 @default.
• W2092532148 hasConceptScore W2092532148C2776957806 @default.
• W2092532148 hasConceptScore W2092532148C2779318504 @default.
• W2092532148 hasConceptScore W2092532148C2781197716 @default.
• W2092532148 hasConceptScore W2092532148C2908647359 @default.
• W2092532148 hasConceptScore W2092532148C33923547 @default.
• W2092532148 hasConceptScore W2092532148C535046627 @default.
• W2092532148 hasConceptScore W2092532148C55493867 @default.
• W2092532148 hasConceptScore W2092532148C61943457 @default.
• W2092532148 hasConceptScore W2092532148C71924100 @default.
• W2092532148 hasConceptScore W2092532148C95457728 @default.
• W2092532148 hasConceptScore W2092532148C99454951 @default.
• W2092532148 hasFunder F4320337351 @default.
• W2092532148 hasIssue "2" @default.
• W2092532148 hasLocation W20925321481 @default.
• W2092532148 hasLocation W20925321482 @default.
• W2092532148 hasLocation W20925321483 @default.
• W2092532148 hasLocation W20925321484 @default.
• W2092532148 hasOpenAccess W2092532148 @default.

• next